文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑转移瘤放疗中的神经保护:德国、奥地利和瑞士的诊疗模式分析——德国放射肿瘤学会神经放射肿瘤学工作组(DEGRO AG-NRO)

Neuroprotection in radiotherapy of brain metastases: A pattern-of-care analysis in Germany, Austria and Switzerland by the German Society for radiation Oncology - working group Neuro-Radio-Oncology (DEGRO AG-NRO).
PubMed 文献 · Clin Transl Radiat Oncol · 2024-04-20

该研究通过在线调查德国放射肿瘤学会注册的放射肿瘤科医生,分析德语国家脑转移瘤放疗中神经保护策略的应用情况。78个中心的医生参与,结果显示全脑放疗在6-10个脑转移瘤患者中仍被70%的医生优先选择,海马保护技术使用率增至89%但仅26%常规使用,美金刚处方率低(14%)。结论认为该领域存在显著异质性且缺乏统一标准,神经保护策略尚未成为日常临床常规。

要点

  • 6-10个脑转移瘤患者中70%的放射肿瘤科医生仍优先选择全脑放疗而非立体定向放疗。
  • 全脑放疗中海马保护技术使用率增至89%,但仅26%的医生常规使用。
  • 美金刚处方率仅14%,神经保护策略尚未成为日常临床常规。

核心结论

  • 德语国家脑转移瘤治疗存在显著异质性,缺乏统一治疗标准。
  • 神经保护策略尚未成为日常临床常规,但使用率在增加。
  • 进一步临床试验、技术机会改善和报销可能推动治疗格局向神经保护性放疗转变。

研究设计与样本

  • 在线调查,针对德国放射肿瘤学会(DEGRO)数据库注册的放射肿瘤科医生,聚焦脑转移瘤治疗模式及神经保护方法的使用。
  • 78个中心的医生参与了调查。

主要发现

  • 6-10个脑转移瘤患者中,70%的放射肿瘤科医生优先选择全脑放疗而非立体定向放疗。
  • 4-5个脑转移瘤患者中,23%的放射肿瘤科医生优先选择全脑放疗。
  • 全脑放疗中使用海马保护的医生比例增至89%,但仅26%常规使用该技术。
  • 美金刚处方率低,14%的放射肿瘤科医生处方。
  • 观察到大学医院更频繁实施神经保护方法的趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Many patients with solid tumors develop brain metastases (BM). With more patients surviving long-term, preservation of neurocognitive function gains importance. In recent years, several methods to delay cognitive deterioration have been tested in clinical trials. However, knowledge on the extent to which these neuroprotective strategies have been implemented in clinical practice is missing. MATERIALS AND METHODS: We performed an online survey regarding treatment patterns of BM in German-speaking countries, focused on the use of neuroprotective approaches. The survey was distributed among radiation oncologists (ROs) registered within the database of the German Society for Radiation Oncology (DEGRO). RESULTS: Physicians of 78 centers participated in the survey. Whole brain radiotherapy (WBRT) is still preferred by 70 % of ROs over stereotactic radiotherapy (SRT) in patients with 6-10 BM. For 4-5 BM WBRT is preferred by 23 % of ROs. The fraction of ROs using hippocampal sparing (HS) in WBRT has increased to 89 %, although the technique is used on a regular basis only by a minority (26 %). The drug memantine is not widely prescribed (14% of ROs). A trend was observed for university hospitals to implement neuroprotective approaches more frequently. CONCLUSION: There is considerable heterogeneity regarding the treatment of BM in German-speaking countries and a general standard of care is lacking. Neuroprotective strategies are not yet standard approaches in daily clinical routine, although usage is increasing. Further clinical trials, as well as improvement of technical opportunities and reimbursement, might further shift the treatment landscape towards neuroprotective radiation treatments in the future.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gleim N, Rühle A, Heider S, et al. Neuroprotection in radiotherapy of brain metastases: A pattern-of-care analysis in Germany, Austria and Switzerland by the German Society for radiation Oncology - working group Neuro-Radio-Oncology (DEGRO AG-NRO). Clin Transl Radiat Oncol. 2024. PMID: 38706724. doi:10.1016/j.ctro.2024.100783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。